Poly(ADP-ribose) polymerase inhibition reverses nitregic neurovascular dysfunctions in penile erectile tissue from streptozotocin-diabetic mice

Matthew R Nangle, Mary A Cotter, Norman E Cameron

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Introduction. Activation of the DNA repair enzyme, poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP), in response to hyperglycemia-driven oxidative/nitrosative stress, may be an important mechanism in the development of vascular and neural complications in diabetes mellitus. However, a role for PARP in diabetic erectile dysfunction (ED) has not been demonstrated.

Aim. To assess whether treatment with a novel PARP-1 inhibitor, GPI 15427, could improve neurovascular dysfunction in corpus cavernosum (CC) from diabetic mice.

Methods. Diabetes was induced by streptozotocin in male MF1 mice; duration was 6 weeks. Intervention GPI 15427 treatment (20 mg/kg/day intraperitoneal [i.p.]) was given for 2 weeks following 4 weeks of untreated diabetes. CC strips were mounted in aerated organ baths for measurement of pharmacological or electrical stimulation-evoked changes in smooth muscle tension.

Main Outcome Measures. Contractile responses to noradrenergic stimulation and to pharmacological agents stimulating endothelium-dependent and -independent relaxation, and nerve-mediated relaxations against a background precontraction.

Results. Contractions in response to phenylephrine or activation of noradrenergic nerves were not significantly altered by diabetes. In contrast, maximum nitrergic nerve-mediated relaxation of phenylephrine-precontracted CC was approximately 28% reduced by diabetes: GPI 15427 treatment completely corrected this diabetic deficit. Similarly, maximal nitric oxide (NO)-mediated endothelium-dependent and -independent relaxations to acetylcholine and sodium nitroprusside, against phenylephrine precontraction, were attenuated approximately 37% and 23% by diabetes, respectively. These deficits were completely reversed by PARP-1 inhibition. Furthermore, GPI 15427 corrected a modest diabetic deficit in sensitivity to nitroprusside (EC50 reduced by 0.14 log units); a similar trend was observed for acetylcholine-induced relaxation.

Conclusions. GPI 15427 treatment provides marked benefits for NO-dependent neurovascular function in diabetic mouse CC. Therefore, PARP-1 inhibition may be worthy of further investigation for diabetes-associated ED. Nangle MR, Cotter MA, and Cameron NE. Poly(ADP-ribose) polymerase inhibition reverses nitrergic neurovascular dysfunctions in penile erectile tissue from streptozotocin-diabetic mice. J Sex Med 2010;7:3396–3403.
Original languageEnglish
Pages (from-to)3396-3403
Number of pages8
JournalThe Journal of Sexual Medicine
Volume7
Issue number10
Early online date26 Apr 2010
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Poly Adenosine Diphosphate Ribose
Streptozocin
Phenylephrine
Nitroprusside
Erectile Dysfunction
Acetylcholine
Endothelium
Nitric Oxide
Nitrergic Neurons
Pharmacology
DNA Repair Enzymes
Muscle Tonus
Poly(ADP-ribose) Polymerases
Diabetes Complications
Therapeutics
Baths
Hyperglycemia
Electric Stimulation
Smooth Muscle
Blood Vessels

Keywords

  • diabetes and erectile dysfunction
  • endothelial dysfunction
  • diabetic neuropathy
  • oxidative stress
  • peroxynitrite
  • poly(ADP-ribose) polymerase (PARP)

Cite this

Poly(ADP-ribose) polymerase inhibition reverses nitregic neurovascular dysfunctions in penile erectile tissue from streptozotocin-diabetic mice. / Nangle, Matthew R; Cotter, Mary A; Cameron, Norman E.

In: The Journal of Sexual Medicine, Vol. 7, No. 10, 10.2010, p. 3396-3403.

Research output: Contribution to journalArticle

@article{bf6f3f4e565e4d0386ce138b381cb501,
title = "Poly(ADP-ribose) polymerase inhibition reverses nitregic neurovascular dysfunctions in penile erectile tissue from streptozotocin-diabetic mice",
abstract = "Introduction. Activation of the DNA repair enzyme, poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP), in response to hyperglycemia-driven oxidative/nitrosative stress, may be an important mechanism in the development of vascular and neural complications in diabetes mellitus. However, a role for PARP in diabetic erectile dysfunction (ED) has not been demonstrated.Aim. To assess whether treatment with a novel PARP-1 inhibitor, GPI 15427, could improve neurovascular dysfunction in corpus cavernosum (CC) from diabetic mice.Methods. Diabetes was induced by streptozotocin in male MF1 mice; duration was 6 weeks. Intervention GPI 15427 treatment (20 mg/kg/day intraperitoneal [i.p.]) was given for 2 weeks following 4 weeks of untreated diabetes. CC strips were mounted in aerated organ baths for measurement of pharmacological or electrical stimulation-evoked changes in smooth muscle tension.Main Outcome Measures. Contractile responses to noradrenergic stimulation and to pharmacological agents stimulating endothelium-dependent and -independent relaxation, and nerve-mediated relaxations against a background precontraction.Results. Contractions in response to phenylephrine or activation of noradrenergic nerves were not significantly altered by diabetes. In contrast, maximum nitrergic nerve-mediated relaxation of phenylephrine-precontracted CC was approximately 28{\%} reduced by diabetes: GPI 15427 treatment completely corrected this diabetic deficit. Similarly, maximal nitric oxide (NO)-mediated endothelium-dependent and -independent relaxations to acetylcholine and sodium nitroprusside, against phenylephrine precontraction, were attenuated approximately 37{\%} and 23{\%} by diabetes, respectively. These deficits were completely reversed by PARP-1 inhibition. Furthermore, GPI 15427 corrected a modest diabetic deficit in sensitivity to nitroprusside (EC50 reduced by 0.14 log units); a similar trend was observed for acetylcholine-induced relaxation.Conclusions. GPI 15427 treatment provides marked benefits for NO-dependent neurovascular function in diabetic mouse CC. Therefore, PARP-1 inhibition may be worthy of further investigation for diabetes-associated ED. Nangle MR, Cotter MA, and Cameron NE. Poly(ADP-ribose) polymerase inhibition reverses nitrergic neurovascular dysfunctions in penile erectile tissue from streptozotocin-diabetic mice. J Sex Med 2010;7:3396–3403.",
keywords = "diabetes and erectile dysfunction, endothelial dysfunction, diabetic neuropathy, oxidative stress, peroxynitrite, poly(ADP-ribose) polymerase (PARP)",
author = "Nangle, {Matthew R} and Cotter, {Mary A} and Cameron, {Norman E}",
year = "2010",
month = "10",
doi = "10.1111/j.1743-6109.2010.01835.x",
language = "English",
volume = "7",
pages = "3396--3403",
journal = "The Journal of Sexual Medicine",
issn = "1743-6095",
publisher = "Elsevier Inc",
number = "10",

}

TY - JOUR

T1 - Poly(ADP-ribose) polymerase inhibition reverses nitregic neurovascular dysfunctions in penile erectile tissue from streptozotocin-diabetic mice

AU - Nangle, Matthew R

AU - Cotter, Mary A

AU - Cameron, Norman E

PY - 2010/10

Y1 - 2010/10

N2 - Introduction. Activation of the DNA repair enzyme, poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP), in response to hyperglycemia-driven oxidative/nitrosative stress, may be an important mechanism in the development of vascular and neural complications in diabetes mellitus. However, a role for PARP in diabetic erectile dysfunction (ED) has not been demonstrated.Aim. To assess whether treatment with a novel PARP-1 inhibitor, GPI 15427, could improve neurovascular dysfunction in corpus cavernosum (CC) from diabetic mice.Methods. Diabetes was induced by streptozotocin in male MF1 mice; duration was 6 weeks. Intervention GPI 15427 treatment (20 mg/kg/day intraperitoneal [i.p.]) was given for 2 weeks following 4 weeks of untreated diabetes. CC strips were mounted in aerated organ baths for measurement of pharmacological or electrical stimulation-evoked changes in smooth muscle tension.Main Outcome Measures. Contractile responses to noradrenergic stimulation and to pharmacological agents stimulating endothelium-dependent and -independent relaxation, and nerve-mediated relaxations against a background precontraction.Results. Contractions in response to phenylephrine or activation of noradrenergic nerves were not significantly altered by diabetes. In contrast, maximum nitrergic nerve-mediated relaxation of phenylephrine-precontracted CC was approximately 28% reduced by diabetes: GPI 15427 treatment completely corrected this diabetic deficit. Similarly, maximal nitric oxide (NO)-mediated endothelium-dependent and -independent relaxations to acetylcholine and sodium nitroprusside, against phenylephrine precontraction, were attenuated approximately 37% and 23% by diabetes, respectively. These deficits were completely reversed by PARP-1 inhibition. Furthermore, GPI 15427 corrected a modest diabetic deficit in sensitivity to nitroprusside (EC50 reduced by 0.14 log units); a similar trend was observed for acetylcholine-induced relaxation.Conclusions. GPI 15427 treatment provides marked benefits for NO-dependent neurovascular function in diabetic mouse CC. Therefore, PARP-1 inhibition may be worthy of further investigation for diabetes-associated ED. Nangle MR, Cotter MA, and Cameron NE. Poly(ADP-ribose) polymerase inhibition reverses nitrergic neurovascular dysfunctions in penile erectile tissue from streptozotocin-diabetic mice. J Sex Med 2010;7:3396–3403.

AB - Introduction. Activation of the DNA repair enzyme, poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP), in response to hyperglycemia-driven oxidative/nitrosative stress, may be an important mechanism in the development of vascular and neural complications in diabetes mellitus. However, a role for PARP in diabetic erectile dysfunction (ED) has not been demonstrated.Aim. To assess whether treatment with a novel PARP-1 inhibitor, GPI 15427, could improve neurovascular dysfunction in corpus cavernosum (CC) from diabetic mice.Methods. Diabetes was induced by streptozotocin in male MF1 mice; duration was 6 weeks. Intervention GPI 15427 treatment (20 mg/kg/day intraperitoneal [i.p.]) was given for 2 weeks following 4 weeks of untreated diabetes. CC strips were mounted in aerated organ baths for measurement of pharmacological or electrical stimulation-evoked changes in smooth muscle tension.Main Outcome Measures. Contractile responses to noradrenergic stimulation and to pharmacological agents stimulating endothelium-dependent and -independent relaxation, and nerve-mediated relaxations against a background precontraction.Results. Contractions in response to phenylephrine or activation of noradrenergic nerves were not significantly altered by diabetes. In contrast, maximum nitrergic nerve-mediated relaxation of phenylephrine-precontracted CC was approximately 28% reduced by diabetes: GPI 15427 treatment completely corrected this diabetic deficit. Similarly, maximal nitric oxide (NO)-mediated endothelium-dependent and -independent relaxations to acetylcholine and sodium nitroprusside, against phenylephrine precontraction, were attenuated approximately 37% and 23% by diabetes, respectively. These deficits were completely reversed by PARP-1 inhibition. Furthermore, GPI 15427 corrected a modest diabetic deficit in sensitivity to nitroprusside (EC50 reduced by 0.14 log units); a similar trend was observed for acetylcholine-induced relaxation.Conclusions. GPI 15427 treatment provides marked benefits for NO-dependent neurovascular function in diabetic mouse CC. Therefore, PARP-1 inhibition may be worthy of further investigation for diabetes-associated ED. Nangle MR, Cotter MA, and Cameron NE. Poly(ADP-ribose) polymerase inhibition reverses nitrergic neurovascular dysfunctions in penile erectile tissue from streptozotocin-diabetic mice. J Sex Med 2010;7:3396–3403.

KW - diabetes and erectile dysfunction

KW - endothelial dysfunction

KW - diabetic neuropathy

KW - oxidative stress

KW - peroxynitrite

KW - poly(ADP-ribose) polymerase (PARP)

U2 - 10.1111/j.1743-6109.2010.01835.x

DO - 10.1111/j.1743-6109.2010.01835.x

M3 - Article

VL - 7

SP - 3396

EP - 3403

JO - The Journal of Sexual Medicine

JF - The Journal of Sexual Medicine

SN - 1743-6095

IS - 10

ER -